1
Cary L Queen, Man Sung Co, William P Schneider, Nicholas F Landolfi, Kathleen L Coelingh, Harold E Selick: Humanized immunoglobulins. Protein Design Labs, Townsend & Townsend & Crew, December 2, 1997: US05693762 (1197 worldwide citation)

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immuno ...


2
Cary L Queen, William P Schneider, Harold E Selick: Polynucleotides encoding improved humanized immunoglobulins. Protein Design Labs, Townsend and Townsend and Crew, December 2, 1997: US05693761 (692 worldwide citation)

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immuno ...


3
Cary L Queen, William P Schneider, Maximiliano Vasquez: FAS ligand fusion proteins and their uses. Protein Design Labs, Townsend & Townsend & Crew, April 4, 2000: US06046310 (26 worldwide citation)

Fas ligand fusion proteins comprising a polypeptide capable of specifically binding an antigen or a cell surface marker are prepared employing recombinant DNA technology for use in, e.g., treatment of autoimmune disorders.


4
William P Schneider: Racemic prostaglandins of the 2-series and analogs thereof. The Upjohn Company, Earl C Spaeth, May 25, 1976: US03959346 (19 worldwide citation)

This invention is racemic PGE.sub.2, racemic PGF.sub.2.sub..alpha., racemic PGF.sub.2.sub..beta., racemic PGA.sub.2, racemic PGB.sub.2, analogs of those, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet ...


5
William P Schneider: 6,7-Didehydro-PGI.sub.1 compounds. The Upjohn Company, Robert A Armitage, December 5, 1978: US04128713 (15 worldwide citation)

This invention relates to certain structural and pharmacological analogs of 5,6-dihydroprostacyclin (PGI.sub.1) wherein an endocyclic double bond is present at the C-6 to C-7 position. These novel unsaturated prostacyclin-type compounds are useful for the pharmacological purposes for which prostacyc ...


6
John E Pike, William P Schneider: 8,12-Dialkyl-PGE, and PGF.sub.1.sub..alpha.. The Upjohn Company, April 27, 1976: US03953499 (6 worldwide citation)

Prostaglandins E.sub.1 -type and F.sub.1 -type compounds of the formula ##EQU1## wherein R is hydrogen or a hydrocarbyl group containing from 1 to 12 carbon atoms, inclusive, wherein W is ##EQU2## or O =, wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 are hyd ...


7
William P Schneider: Thromboxane B analogs. The Upjohn Company, Robert A Armitage, October 4, 1977: US04052552 (4 worldwide citation)

The present specification provides novel intermediates and novel processes for the synthesis of various side chain and skeletal analogs of Thromboxane B.sub.2 (11.beta.-homo-11a-oxa-PGF.sub.2.alpha.). These analogs are particularly and especially useful as reproductive cycle control agents.


8
William P Schneider: Intermediate for synthesis of Thromboxane B.sub.2. The Upjohn Company, Robert A Armitage, April 19, 1977: US04018804 (3 worldwide citation)

The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 (11a-homo-11a-oxa-PGF.sub.2), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in ...


9
William P Schneider: Racemic prostaglandins of the 2-series and analogs thereof. The Upjohn Company, September 21, 1976: US03981880 (2 worldwide citation)

This invention is racemic PGE.sub.2, racemic PGF.sub.2.sub..alpha., racemic PGF.sub.2.sub..beta., racemic PGA.sub.2, racemic PGB.sub.2, analogs of those, and processes of making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet a ...


10
William P Schneider: Process for preparing thromboxane B compounds from prostaglandin f.alpha. c o. The Upjohn Company, Robert A Armitage, January 24, 1978: US04070384 (2 worldwide citation)

The present specification provides novel intermediates and novel processes for the synthesis of various side chain and skeletal analogs of Thromboxane B.sub.2 (11.beta.-homo-lla-oxa-PGF.sub.2.alpha.). These analogs are particularly and especially useful as reproductive cycle control agents.